Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Praxis Precision Medicines filings document regulatory disclosures for a CNS-focused biopharmaceutical issuer with common stock listed on the Nasdaq Global Select Market under PRAX. Its Form 8-K and 8-K/A reports cover material events, operating and financial results, clinical and regulatory updates, capital-structure disclosures, and leadership or board changes.
The company’s filing record includes disclosures related to ulixacaltamide HCl for essential tremor, elsunersen in SCN2A developmental and epileptic encephalopathy, and broader pipeline programs in movement disorders and epilepsy. Proxy materials address annual meeting matters, board composition, committee assignments, executive compensation, equity awards and other governance subjects.
Praxis Precision Medicines, Inc. is reshaping its at-the-market equity financing. The company terminated its 2024 Open Market Sale Agreement with Jefferies, under which it had sold 1,368,176 shares of common stock for aggregate gross proceeds of approximately $86.2 million, with no termination penalties. As a result, no further shares will be sold under that 2024 ATM program.
The company has entered into a new 2025 Sales Agreement with TD Securities (USA) LLC (TD Cowen) to sell up to $250 million of common stock from time to time through an at-the-market offering. Praxis will set sale parameters and pay TD Cowen a commission of up to 3.0% of gross proceeds, and sales will be made under its effective shelf registration statement and related prospectus supplement.
Praxis Precision Medicines, Inc. filed a prospectus supplement for an "at the market" offering to sell up to $250,000,000 of common stock through TD Securities (USA) LLC (TD Cowen) as sales agent. The offering may be conducted from time to time on Nasdaq under ticker PRAX; the prospectus cites a last reported sale price of $44.94 per share on September 2, 2025. TD Cowen may receive commissions up to 3.0% of gross sales and will be treated as an underwriter for Securities Act purposes. The filing discloses 21,049,585 shares outstanding as of August 31, 2025 and illustrates an example issuance of 5,562,972 shares (assumed) resulting in up to 26,612,557 post-offering shares. Net tangible book value was $404.2 million ($19.21/share) as of June 30, 2025 and would be $646.4 million ($24.30/share) after the assumed sale, implying $20.64 per-share dilution to new investors. Proceeds are for research and clinical development, working capital and general corporate purposes. The prospectus emphasizes material risks, broad managerial discretion over proceeds, potential dilution, and incorporation by reference of SEC filings.
Adage Capital Management and two principals report beneficial ownership of 2,374,085 shares of Praxis Precision Medicines, Inc. (PRAX), representing 11.28% of the 21,045,781 shares outstanding as of July 31, 2025. The filing is a Schedule 13G/A indicating the stake is held in the ordinary course of business and not to influence control. The reported holdings are held directly by Adage Capital Partners, L.P. and are disclosed by Adage Capital Management, L.P., Robert Atchinson and Phillip Gross, each showing shared voting and dispositive power over 2,374,085 shares and no sole voting or dispositive power. The filing cites the issuers principal executive office in Boston and uses the CUSIP 74006W207.
Adage Capital Management and two principals report beneficial ownership of 2,374,085 shares of Praxis Precision Medicines, Inc. (PRAX), representing 11.28% of the 21,045,781 shares outstanding as of July 31, 2025. The filing is a Schedule 13G/A indicating the stake is held in the ordinary course of business and not to influence control. The reported holdings are held directly by Adage Capital Partners, L.P. and are disclosed by Adage Capital Management, L.P., Robert Atchinson and Phillip Gross, each showing shared voting and dispositive power over 2,374,085 shares and no sole voting or dispositive power. The filing cites the issuers principal executive office in Boston and uses the CUSIP 74006W207.
Adage Capital Management, L.P. reported an initial Section 16 filing for Praxis Precision Medicines, Inc. (PRAX) disclosing 2,374,085 shares beneficially owned indirectly. The filing states these shares are held directly by Adage Capital Partners, L.P. (ACP) and that Adage Capital Management, L.P. (ACM) serves as ACP's investment manager with discretionary authority over the portfolio. Robert Atchinson and Phillip Gross are identified as managing members of related Adage entities. The reporting persons are listed as Directors and as a 10% owner relationship to the issuer. The filing includes standard Section 16 disclaimers that each reporting person disclaims beneficial ownership except for any pecuniary interest, and it is signed by Adage and the two individuals on 08/19/2025.
Point72-associated entities and Steven A. Cohen report collective beneficial ownership of Praxis Precision Medicines (PRAX) common stock totaling 1,531,038 shares, representing 7.3% of the outstanding class as of June 30, 2025. The filing shows 1,465,105 shares reported by Point72 Asset Management/Point72 Capital Advisors (7.0%) and 65,933 shares held by related entities (0.3%). The total includes 511,030 shares issuable upon exercise of warrants, which are counted in the denominator used for the percent calculation. The report states these holdings are not intended to change or influence control of the issuer.
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 1,625,000 shares of Praxis Precision Medicines common stock, representing 7.72% of the outstanding class. The shares are held through Cormorant-managed funds (the "Cormorant Funds") and the filing attributes voting and dispositive authority as shared rather than sole power.
The filing notes that the Cormorant Funds have the economic rights to dividends or sale proceeds and identifies Cormorant Global Healthcare Master Fund, LP as a fund with rights to more than 5% of the reported shares. The statement clarifies it is filed on behalf of both reporting persons and disclaims that the filing alone establishes beneficial ownership for purposes of Section 13.
This amendment to a Schedule 13G reports that Janus Henderson Group plc and an affiliated fund hold material stakes in Praxis Precision Medicines common stock. The filing shows Janus Henderson Group plc beneficially owns 2,533,405 shares, representing 12.4% of the class, with shared voting and dispositive power over those shares. Janus Henderson Biotech Innovation Master Fund Ltd is reported to beneficially own 1,186,586 shares ( 5.8% ).
The filing identifies indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers and includes a certification that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control. A power of attorney authorizes certain compliance officers to file and amend reporting documents on behalf of Janus Henderson.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, report beneficial ownership of 1,974,585 shares of Praxis Precision Medicines common stock, representing 9.69% of the outstanding class. The shares are directly held by Adage Capital Partners, L.P. and the percentage is calculated using an aggregate of 20,368,982 shares outstanding as reported by the company.
The filing shows shared voting and shared dispositive power for the reporting persons and no sole voting or dispositive power. It also certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Reporting entities are organized in Delaware and the named individuals are U.S. citizens.